Is LQDA or LYEL more undervalued in 2026?

CirclFi compares Liquidia Corporation (LQDA) and Lyell Immunopharma, Inc. (LYEL) using 13 institutional-grade valuation models. LQDA has a Quality of Company score of 6.7/10 while LYEL scores 4.8/10.

Which is a better buy — LQDA or LYEL?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LQDA and LYEL valuations compare?

LQDA at $61.86 and LYEL at $17.33 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LQDA vs LYEL Valuation Comparison 2026 — Intrinsic Value Analysis

LQDA

Pharmaceutical Preparations

Liquidia Corporation

Quality

6.7

out of 10

Value Trap

SAFE

Price

$61.86

Last close

Models

13/13

Active

LYEL

Pharmaceutical Preparations

Lyell Immunopharma, Inc.

Quality

4.8

out of 10

Value Trap

LOW

Price

$17.33

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	LQDA Fair Value	LQDA Upside	LYEL Fair Value	LYEL Upside
Bayesian DCF	Intrinsic	$2.28	-96.3%	$4.45	-74.3%
Earnings Power Value	Intrinsic	$5.66	-90.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.69	-98.9%	$14.95	-13.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LQDA vs LYEL — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LQDA vs LYEL — Which Stock Is More Undervalued?

LQDA scores higher with a 6.7/10 quality rating vs LYEL's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Liquidia Corporation (LQDA) and Lyell Immunopharma, Inc. (LYEL) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LQDA currently trades at $61.86 with a QOC of 6.7/10, while LYEL trades at $17.33 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).